Myriad Genetics, Inc.
Myriad Genetics, Inc. (Nasdaq: MYGN) develops and commercializes molecular diagnostic tests that help patients and healthcare providers assess disease risk and progression, select treatments, and make prenatal and mental health care decisions. Its offerings span oncology, women’s health, and mental health, serving… From the company’s description.
Over the twelve months to Sep 30, 2026, Myriad Genetics, Inc. reported revenue of $803.60M, down 2.6% from a year earlier, and a net loss of $129.10M. Its operating margin was −14.3%, and operations used $19.90M in cash. In fiscal 2025, it reported revenue of $824.50M, down 1.6% from fiscal 2024, and a net loss of $365.90M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Myriad Genetics, Inc. does
In the company’s own words
Myriad Genetics, Inc. (Nasdaq: MYGN) develops and commercializes molecular diagnostic tests that help patients and healthcare providers assess disease risk and progression, select treatments, and make prenatal and mental health care decisions. Its offerings span oncology, women’s health, and mental health, serving patients, physicians, health systems, and biopharmaceutical partners. Oncology tests assess hereditary cancer risk, tumor characteristics, treatment eligibility, and residual disease; women’s health products include prenatal and carrier screening; and GeneSight analyzes how genetics may affect response to psychiatric medications. Major brands include MyRisk, BRACAnalysis, MyChoice CDx, Prolaris, Precise Tumor, Precise MRD, Prequel, Foresight, FirstGene, SneakPeek, and GeneSight. Myriad primarily sells through its sales force in the United States and Japan, and uses indirect channels and partnerships to reach customers in Europe and Asia-Pacific. The company reports its business across these three clinical areas and had approximately 2,700 full-time equivalent employees as of December 31, 2025. Its website is www.myriad.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Chemicals
- Headquarters
- SALT LAKE CITY, UT
- Fiscal year end
- December
- CIK
- 899923
- SIC
- 2835
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Myriad Genetics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Myriad Genetics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Myriad Genetics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Myriad Genetics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Myriad Genetics, Inc.'s last four quarterly filings that the numbers alone won't show?”